|"LifeTalks" by Roche |
The first LifeTalk started in Basel, Switzerland on November 2, with the next ones scheduled in Singapore in February and San Francisco in May, with over 40 local events worldwide following.
LifeTalks was designed to inspire and stimulate novel and diverse thinking by connecting speakers with varied backgrounds and perspectives across the healthcare field to generate positive ideas and solutions to the challenging problems that humanity is facing in healthcare, science, and sustainability. What will be the future for healthcare after COVID-19? What risks may arise and how can they be prevented? How can we overcome this crisis together? These are just some of the big questions among many that will be addressed in the LifeTalks series, either in-person or virtual.
At the first virtual LifeTalk in Basel, Roche brought up the question: Is crisis leading to innovation? Because of COVID-19, lives around the world were disrupted, schools were closed, and the economy was hit hard. However, despite the circumstances, solid cooperation, consensus, and willingness to share innovative and creative ideas were extensively shown among global scientists, associations, enterprises, and government departments and agencies to research and develop an accurate diagnosis and effective vaccines, as well as advanced treatment solutions.
The panel discussion was joined by renowned healthcare experts such as Dr. Severin Schwan, CEO of Roche Group; Christiane Woopen, professor for LifeEthics at the University of Bonn; and Kate Bingham, chair of the UK COVID-Vaccine Taskforce in 2020, among others.
In the two hours of discussion, LifeTalk’s speakers addressed many important issues to find effective and comprehensive solutions in pandemic prevention as well as to set up a powerful post-pandemic recovery plan. Some sharings will help to accelerate clinical development and regulatory processes in drug and vaccine development, such as applying AI and analysing data to benefit diagnosis and treatment. The topic of healthcare access for patients around the world was also extensively discussed.
Roche is a global pioneer in pharmaceuticals and diagnostics, focusing on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare.
Roche is also the world’s largest biotech company, with differentiated medicines in oncology, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system; and the world leader in in-vitro diagnostics and tissue-based cancer diagnostics.
Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries. In 2020, Roche employed more than 100,000 people worldwide and invested around $13 billion in research and development.